1. Home
  2. ARQQ vs HELP Comparison

ARQQ vs HELP Comparison

Compare ARQQ & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arqit Quantum Inc.

ARQQ

Arqit Quantum Inc.

HOLD

Current Price

$16.53

Market Cap

315.7M

Sector

Technology

ML Signal

HOLD

HELP

Cybin Inc. Common Stock

N/A

Current Price

$6.76

Market Cap

303.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARQQ
HELP
Founded
2017
N/A
Country
United Kingdom
Canada
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
315.7M
303.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ARQQ
HELP
Price
$16.53
$6.76
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$60.00
N/A
AVG Volume (30 Days)
270.7K
465.6K
Earning Date
12-09-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$530,000.00
N/A
Revenue This Year
$381.13
N/A
Revenue Next Year
$212.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.00
$4.81
52 Week High
$62.00
$10.59

Technical Indicators

Market Signals
Indicator
ARQQ
HELP
Relative Strength Index (RSI) 29.53 51.00
Support Level $15.89 $5.88
Resistance Level $17.45 $6.65
Average True Range (ATR) 1.57 0.59
MACD -0.23 -0.01
Stochastic Oscillator 7.34 70.13

Price Performance

Historical Comparison
ARQQ
HELP

About ARQQ Arqit Quantum Inc.

Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: